DexCom DXCM Return on equity
Other financials
Where this comes from
Calculated from DexCom’s reported figures.
Based on trailing twelve months.
The official record: DexCom’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about DexCom's return on equity.
Connect your AI assistant and see it in context, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is DexCom's return on equity?
- DexCom (DXCM) reported return on equity of 35.6% in Q1 2026.
- How has DexCom's return on equity changed year-over-year?
- DexCom's return on equity increased by 50.2% year-over-year, from 23.7% to 35.6%.
- What is the long-term trend for DexCom's return on equity?
- Over 4 years (2021 to 2025), DexCom's return on equity has grown at a -2.9% compound annual growth rate (CAGR), from 125.4% to 111.7%.
- What does return on equity mean?
- How much profit the company earns on the money shareholders have invested.
- How do you interpret return on equity?
- Higher is better, but very high ROE can be manufactured by leverage — a thin equity base inflates the ratio. Read it next to debt-to-equity and ROIC to tell genuine returns from balance-sheet engineering.
- How does return on equity compare across companies?
- Comparable across peers, with the leverage caveat. Negative or near-zero equity makes ROE meaningless, so it is suppressed there.